Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer

This prospective Phase II study was undertaken to evaluate intermittent androgen suppression as a form of therapy in men with localized prostate cancer who failed after they received external beam irradiation.

[1]  N. Sato,et al.  Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. , 2004, Urology.

[2]  J. Hines,et al.  Long-Term Outcomes in Patients with Prostate Cancer Managed with Intermittent Androgen Suppression , 2004, Urologia Internationalis.

[3]  S. Goldenberg,et al.  Intermittent androgen suppression , 2004, BJU international.

[4]  L. Collette,et al.  Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. , 2003, European urology.

[5]  A. Bono,et al.  Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer , 2003, Oncology.

[6]  B. Escudier,et al.  A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. , 2003, European urology.

[7]  A. De la taille,et al.  Intermittent androgen suppression in patients with prostate cancer , 2003, BJU international.

[8]  P. Bonnet,et al.  Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. , 2002, Clinical prostate cancer.

[9]  L. Lenormand,et al.  Intermittent Androgen Suppression in the Treatment of Metastatic Prostate Cancer , 2000, European Urology.

[10]  M. Scholz,et al.  Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. , 2000, The oncologist.

[11]  M. Gleave,et al.  Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. , 2000, Molecular urology.

[12]  N. Bruchovsky,et al.  Prostate cancer: molecular biology of early progression to androgen independence. , 1999, Endocrine-related cancer.

[13]  J. Crook,et al.  Intermittent androgen suppression in the management of prostate cancer. , 1999, Urology.

[14]  P. Carroll,et al.  Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. , 1998, Urology.

[15]  D. Dearnaley,et al.  A pilot study of intermittent androgen deprivation in advanced prostate cancer. , 1998, British journal of urology.

[16]  G. Williams,et al.  Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. , 1997, Urology.

[17]  G. Theyer,et al.  Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. , 1997, British Journal of Cancer.

[18]  A. Coldman,et al.  Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  W. Ellis,et al.  Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. , 1996, Urology.

[20]  M. Gleave,et al.  Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  U. Tunn.  Intermittent endocrine therapy of prostate cancer. , 1996, European urology.

[22]  M. Gleave,et al.  Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. , 1995, Urology.

[23]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[24]  M. Terris,et al.  Determination of prostate volume by transrectal ultrasound. , 1991, The Journal of urology.

[25]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[26]  L. Klotz,et al.  Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.

[27]  N. Bruchovsky,et al.  Pathological growth of androgensensitive tissues resulting from latent actions of steroid hormones. , 1978, Journal of toxicology and environmental health.

[28]  R. Noble.  Hormonal control of growth and progression in tumors of Nb rats and a theory of action. , 1977, Cancer research.

[29]  C. Keysser.  Neoplastic Development, Vol. 2 , 1976 .

[30]  N. Bruchovsky,et al.  Androgen receptors: relationship to growth response and to intracellular androgen transport in nine variant lines of the Shionogi mouse mammary carcinoma. , 1975, Biochimica et biophysica acta.

[31]  N. Bruchovsky,et al.  Hormonal effects on cell proliferation in rat prostate. , 1975, Vitamins and hormones.

[32]  N. Bruchovsky,et al.  The effects of 5alpha-dihydrotestosterone on the kinetics of cell proliferation in rat prostate. , 1974, The Biochemical journal.

[33]  N. Bruchovsky,et al.  Effect of duration of the period after castration on the response of the rat ventral prostate to androgens. , 1974, The Biochemical journal.

[34]  N. Bruchovsky,et al.  The effects of testosterone, 5 -dihydrotestosterone and adenosine 3',5'-monophosphate on cell proliferation and differentiation in rat prostate. , 1973, Biochimica et biophysica acta.

[35]  K. Yamaguchi,et al.  An androgen-dependent tumor derived from a hormone- independent spontaneous tumor of a female mouse , 1964 .